{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:54:39Z","timestamp":1762865679371,"version":"3.37.3"},"reference-count":41,"publisher":"Wiley","issue":"S60","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4527,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1996,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>Pharmacogenetic differences in the handling of and response to drugs can markedly alter the risk of severe idiosyncratic adverse drug reactions, including neutropenia, agranulocytosis and aplastic anaemia. Inherited deficiencies of drug metabolizing enzymes can shunt the metabolism of drugs to metabolites which are directly toxic (e.g. 6\u2010mercaptopurine metabolism to 6\u2010thioguanine nucleotides) or towards electrophilic metabolites which can kill cells and\/or lead to a host immune response (e.g. sulphonamide metabolism to hydroxylamine metabolites). Defects in detoxification pathways (e.g. glutathione conjugation) similarly can predispose patients to adverse outcomes. The advent of molecular screening tools to define individual (rather than population) risk may lead to the use of clinical laboratory tests to identify\/predict idiosyncratic adverse drug reactions.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1996.tb01653.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T08:55:36Z","timestamp":1279443336000},"page":"93-97","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacogenetics and blood dyscrasias"],"prefix":"10.1111","volume":"57","author":[{"given":"Stephen P.","family":"Spielberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","article-title":"Pharmacogenetics: from scientific curiosity to a central theme in drug development and therapeutics","volume":"2","author":"Spielberg SP","year":"1995","journal-title":"Can J Clin Pharm"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426010-00005"},{"key":"e_1_2_1_4_2","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum RM","year":"1980","journal-title":"Am J Hum Genet"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00483962"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0022-3565(25)33170-8","article-title":"Pharmacogenetics of human thiopurine methyltransferase: kidney\u2014erythrocyte correlation","volume":"22","author":"Woodson LC","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_7_2","first-page":"134","article-title":"Thiopurine methyltransferase pharmacogenetics: human liver enzyme activity","volume":"43","author":"Szymlanski CL","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.105"},{"key":"e_1_2_1_9_2","first-page":"18","article-title":"Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6\u2010thioguanine nucleotide concentrations","volume":"46","author":"Lennard L","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.119"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92511-6"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"e_1_2_1_13_2","first-page":"2308","article-title":"In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans","volume":"43","author":"Spielberg SP","year":"1984","journal-title":"Fed Proc"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90706-4"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.24.11825"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90151-5"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2630020708"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.V84.8.2767.2767","article-title":"p22\u2010phox\u2010deficient chronic granulomatous disease: reconstitution by retrovirus\u2010mediated expression and identification of a biosynthetic intermediate of gp91phox","volume":"84","author":"Porter CD","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood.V81.8.2131.2131","article-title":"Improvement in superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines","volume":"81","author":"Jendrossek V","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(77)80819-6"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000401616"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.4049\/jimmunol.120.4.1181","article-title":"Microtubule assembly and function in normal and glutathione synthetase deficient cells","volume":"120","author":"Oliver JM","year":"1978","journal-title":"J Immunol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb01126.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197910253011702"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.9"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110030"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1139\/y85-225"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1139\/y85-081"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-2-179"},{"volume-title":"The acetylator genes and drug response","year":"1987","author":"Weber WW","key":"e_1_2_1_30_2"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02372.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.3"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.57"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0090-9556(25)08652-0","article-title":"Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine","volume":"18","author":"Cribb AE","year":"1990","journal-title":"Drug Metab Disp"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0090-9556(25)06552-3","article-title":"N4\u2010hydroxylation of sulfamethoxazole by cytochrome P450 of the CYP2C subfamily, and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes","volume":"23","author":"Cribb AE","year":"1995","journal-title":"Drug Metab Disp"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0026-895X(25)09508-2","article-title":"Peroxidase\u2010dependent oxidation of sulfonamides by monocytes and neutrophils from man and dog","volume":"38","author":"Cribb AE","year":"1990","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.8"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-4-286"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00347744"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0090-9556(25)08967-6","article-title":"Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: implications for idiosyncratic toxicity","volume":"19","author":"Cribb AE","year":"1991","journal-title":"Drug Metab Disp"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90334-2"},{"key":"e_1_2_1_42_2","article-title":"In vitro formation, disposition, and toxicity of N\u2010acetoxysulfamethoxazole, a potential mediator of sulfamethoxazole toxicity","author":"Nakamura H","year":"1996","journal-title":"J Pharmacol Exp Ther"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1996.tb01653.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1996.tb01653.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T02:27:03Z","timestamp":1740277623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1996.tb01653.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,12]]},"references-count":41,"journal-issue":{"issue":"S60","published-print":{"date-parts":[[1996,12]]}},"alternative-id":["10.1111\/j.1600-0609.1996.tb01653.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb01653.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[1996,12]]}}}